These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

453 related items for PubMed ID: 18525301

  • 1. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Amato RJ, Malya R, Rawat A.
    Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
    Amato RJ, Morgan M, Rawat A.
    Cancer; 2006 Apr 01; 106(7):1498-506. PubMed ID: 16475152
    [Abstract] [Full Text] [Related]

  • 3. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
    Schrader AJ, Heidenreich A, Hegele A, Olbert P, Varga Z, Hofmann R.
    Aktuelle Urol; 2006 Nov 01; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.
    Clin Cancer Res; 2000 Apr 01; 6(4):1267-72. PubMed ID: 10778950
    [Abstract] [Full Text] [Related]

  • 5. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM.
    Cancer; 2000 Mar 15; 88(6):1317-24. PubMed ID: 10717612
    [Abstract] [Full Text] [Related]

  • 6. Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial.
    Schmidinger M, Steger G, Wenzel C, Locker GJ, Budinsky AC, Brodowicz T, Kramer G, Marberger M, Zielinski CC, Austrian Renal Cell Carcinoma Study Group.
    J Immunother; 2001 Mar 15; 24(3):257-62. PubMed ID: 11394504
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
    Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, Torti FM.
    Urology; 2004 Jun 15; 63(6):1061-5. PubMed ID: 15183950
    [Abstract] [Full Text] [Related]

  • 8. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
    Garcia JA, Mekhail T, Elson P, Wood L, Bukowski RM, Dreicer R, Rini BI.
    BJU Int; 2012 Jan 15; 109(1):63-9. PubMed ID: 21244601
    [Abstract] [Full Text] [Related]

  • 9. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate.
    Amato RJ, Hernandez-McClain J, Henary H.
    Urol Oncol; 2009 Jan 15; 27(1):8-13. PubMed ID: 18367123
    [Abstract] [Full Text] [Related]

  • 10. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.
    Pacheco AV, Rasila K, Lee SJ, Rabinowitz I, Elias L, Lee FC, Verschraegen CF.
    Urol Oncol; 2008 Jan 15; 26(6):610-5. PubMed ID: 18367103
    [Abstract] [Full Text] [Related]

  • 11. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients.
    Lissoni P, Mengo S, Bucovec R, Brivio F, Fumagalli L, Tancini G, Gardani GS.
    In Vivo; 2003 Jan 15; 17(1):73-5. PubMed ID: 12655794
    [Abstract] [Full Text] [Related]

  • 12. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
    Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R.
    Cancer; 2002 Aug 15; 95(4):758-65. PubMed ID: 12209719
    [Abstract] [Full Text] [Related]

  • 13. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
    Culine S, Iborra F, Mottet N, Avancès C, de Graeve B, Volpé P, Vignoud J, Bringer JP, Marroncle M, Le Pellec L, Ayuso D, Jansen E, Faix A, Rebillard X.
    Am J Clin Oncol; 2006 Apr 15; 29(2):148-52. PubMed ID: 16601433
    [Abstract] [Full Text] [Related]

  • 14. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH, Hank JA, Khorsand M, Storer B, Borchert A, Huseby-Moore K, Burns D, Wesly O, Albertini MR, Wilding G, Sondel PM.
    Clin Cancer Res; 1996 Feb 15; 2(2):319-30. PubMed ID: 9816175
    [Abstract] [Full Text] [Related]

  • 15. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
    Lutzky J, Weber R, Nunez Y, Gillett M, Spitler L.
    J Immunother; 2009 Jan 15; 32(1):79-85. PubMed ID: 19307996
    [Abstract] [Full Text] [Related]

  • 16. Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome.
    Westermann J, Hecker AC, Flörcken A, Dörken B, Pezzutto A.
    J Immunother; 2009 Jan 15; 32(6):667-75. PubMed ID: 19483643
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
    Gez E, Rubinov R, Gaitini D, Meretyk S, Best LA, Native O, Stein A, Erlich N, Beny A, Zidan J, Haim N, Kuten A.
    Cancer; 2002 Oct 15; 95(8):1644-9. PubMed ID: 12365011
    [Abstract] [Full Text] [Related]

  • 18. Lenalidomide therapy for metastatic renal cell carcinoma.
    Amato RJ, Hernandez-McClain J, Saxena S, Khan M.
    Am J Clin Oncol; 2008 Jun 15; 31(3):244-9. PubMed ID: 18525302
    [Abstract] [Full Text] [Related]

  • 19. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S, Leonardi V, Danova M, Porta C, Ferrari S, Fincato G, Citarrella P.
    Haematologica; 1999 Nov 15; 84(11):1016-23. PubMed ID: 10553163
    [Abstract] [Full Text] [Related]

  • 20. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A, Delva R, Gomez F, Chevreau C, Douillard JY, Peny J, Coudert B, Négrier S, Groupe Français d'Immunothérapie.
    Cancer; 2002 Dec 01; 95(11):2324-30. PubMed ID: 12436438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.